Chrysos is performing well in states with Medicaid coverage, expanding to more states. Vibativ is approved in Saudi Arabia with global market initiatives. New clinical data shows Caldolor's benefits in reducing adverse reactions. Financial highlights include $9.1 million in net revenue and reduced operating expenses.